Navigation Links
Zogenix and Astellas Enter Exclusive Co-Promotion Agreement in the US for Newly Approved Sumavel(TM) DosePro(TM)
Date:8/3/2009

SAN DIEGO and DEERFIELD, Ill., August 3 /PRNewswire/ -- Zogenix, Inc. ("Zogenix"), a privately held pharmaceutical company and Astellas Pharma US, Inc. ("Astellas"), announced today their exclusive co-promotion agreement for Sumavel DosePro (sumatriptan injection) needle-free delivery system. Sumavel DosePro received FDA approval in July 2009 and is a first-of-its-kind needle-free delivery system for subcutaneous sumatriptan, a treatment that provides migraine relief within 10 minutes for some patients.

"Partnering with Astellas is a significant milestone for Zogenix which will allow us to bring this cutting edge treatment to a broader number of people suffering from migraines," said Roger Hawley, CEO and director of Zogenix, Inc. "It was essential that we found the right partner for the introduction of our first product, Sumavel DosePro. Astellas will bring significant sales and marketing experience to our promotional efforts and help ensure the successful launch of Sumavel DosePro."

According to the National Headache Foundation, acute migraines affect nearly 30 million Americans, primarily women between the ages of 25 and 40, who are treated by primary care physicians and neurologists. Tablets are a treatment option for some of these migraine sufferers, but not all patients are satisfied with tablet therapy. Fast-acting, non-oral options are needed particularly for those who experience migraine episodes associated with sudden onset, waking, nausea or vomiting.

"Part of Astellas' corporate strategy is to continue establishing successful partnerships, so we are especially pleased to bring Sumavel DosePro to market with Zogenix," said Seigo Kashii, president and CEO of Astellas. "We believe this innovative product will have a broad appeal which complements our current primary care efforts and enriches our local portfolio. We look forward to our collaboration with Zog
'/>"/>

SOURCE Astellas Pharma US, Inc.; Zogenix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Cardiome And Astellas Announce Regulatory Update
2. FDA Approves Additional Indication for Astellas MYCAMINE(R)
3. Astellas/GlaxoSmithKlines Vesicare Has Advantages Over Pfizers Detrol LA/Detrusitol XL in Reducing Episodes of Urge Urinary Incontinence
4. Astellas Launches Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia
5. Astellas Announces New Vice President of Marketing
6. Astellas Hires New Vice President of Compliance
7. Astellas Adds CNS Therapy Area Leader to Global R&D Team
8. Astellas Names Head of Global R&D Operations
9. NeurogesX and Astellas Enter Commercialization Agreement for Qutenza(TM)
10. AUA Foundation names the 2009 Astellas Rising Stars in Urology award winners
11. Scientists Spot Brains Free Will Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... based on administering antidepressants for acute and chronic ... are needed to determine whether these drugs should ... basis., Dr. Ian Gilron, a professor and director ... Anesthesiology, and his team of seven researchers reviewed ... antidepressants for pain relief post-surgery would work more ...
(Date:8/29/2014)... Village, IL (PRWEB) August 29, 2014 ... in hearing wellness solutions, is on its way to ... at the San Diego Convention Center to exhibit and ... who work in high-noise industrial environments. Etymotic’s safety earphones ... hottest wearable technology devices at the show. , ...
(Date:8/29/2014)... IL (PRWEB) August 29, 2014 ... “The Safety Chick” who profiled a handful of ... Earphones from Etymotic Research. This year, many schools ... and Etymotic, an innovator of hearing wellness solutions, ... Their ETY•Kids Safe-Listening Earphones, offered in yellow, pink ...
(Date:8/29/2014)... London, UK (PRWEB) August 29, 2014 ... growing ones in the in-vitro diagnostics industry; it is ... The growth is driven by the ongoing spread of ... a primary factor associated with the upsurge of opportunistic ... diagnostic; and a broader availability of immunosuppressive medicines. Although ...
(Date:8/29/2014)... Edvance360, a leading provider of eLearning ... teaching, as well as 2011 winner and six-time-finalist for ... System, announced that Brooke Education Services, Northwest Academy, Typewell, ... Advertising Bureau of Canada (IAB Canada), StarSVCS, and HMG ... delighted to welcome each new client to the growing ...
Breaking Medicine News(10 mins):Health News:Antidepressants show potential for postoperative pain 2Health News:Etymotic’s Safe Listening Earphones and Earplugs Headed For The 2014 NSC Safety Expo 2Health News:The Today Show Features ETY•Kids® Safe-Listening Earphones by Etymotic 2Health News:Infectious Disease Testing Universe Examined in New VPG Research Report Available at MarketPublishers.com 2Health News:Infectious Disease Testing Universe Examined in New VPG Research Report Available at MarketPublishers.com 3Health News:Edvance360 Continues to Experience Growth in Corporate, K-12, Health, and Non-Profit Sectors 2
... price for a 30-second advertising spot in the 2012 Super Bowl ... study suggests that, for advertisers, it may not really matter if ... But for the sake of companies forking out big bucks on ... The study by an Oregon State University researcher, which is ...
... -- Teens who think of themselves as thrill-seekers and who ... likely to drive with other teens in the car, which ... finds. And a second study of teens involved in ... distraction and risky driving behavior often played a role. ...
... HealthDay Reporter , THURSDAY, Jan. 26 (HealthDay News) -- ... provide insight into whether patients are at high risk of ... cancer. The test, which is currently available, could ... prevent the cancer from returning. There are caveats: The ...
... a "common sense" decision to start the company in a ... belt. , "We wanted to give better stroke care," said ... of Neurology at the Medical College of Georgia at Georgia ... and his colleagues were frustrated that nearly five years after ...
... By Denise Mann HealthDay Reporter , THURSDAY, Jan. ... for liver cancer among people with hepatitis B, a new study ... hepatitis B virus, is one of the main causes of liver ... have shown promise in reducing risk for cancer. Other studies have ...
... a sensitive non-invasive marker of early lung disease in young ... from Australian researchers. "We found that LCI is elevated ... airway inflammation and Pseudomonas aeruginosa," said Yvonne Belessis, MBBS, MPH, ... may not only be a marker of early CF lung ...
Cached Medicine News:Health News:Sporting event ads viewed favorably - especially if the game is close 2Health News:Teen Driver's Friends Can Be Dangerous Distraction, Studies Find 2Health News:Test Might Predict Risk of Lung Cancer's Return 2Health News:Georgia Bio honors biotech company that enables stroke care 2Health News:Georgia Bio honors biotech company that enables stroke care 3Health News:Statins May Stave Off Liver Cancer in People With Hepatitis B 2Health News:Early cystic fibrosis lung disease detected by bronchoalveolar lavage and lung clearance index 2
(Date:8/29/2014)... 2014 The Competitive Intelligence (CI) function is ... CI leaders who adjust will succeed, and those who ... Best Practices, LLC study CI leaders from 32 biopharmaceutical ... - Use secondary research whenever possible - it,s ... - Internal staff who are creative thinkers provide the ...
(Date:8/29/2014)... -- Pomerantz LLP has filed a class action lawsuit ... EDAP ) and certain of its officers.  The ... District of New York , and ... consisting of all persons or entities who purchased EDAP ... inclusive (the "Class Period"). This class action seeks to recover ...
(Date:8/29/2014)...   Mast Therapeutics, Inc. (NYSE MKT: ... Santosh Vetticaden, Chief Medical Officer and Senior Vice ... reasons, in mid-September.  Edwin L. Parsley , ... which Mast acquired earlier this year, will assume ... Chief Medical Officer.  Dr. Parsley previously was with ...
Breaking Medicine Technology:Using the Competitive Intelligence Function to Drive Better Business Decisions in the Pharmaceutical Sector 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A. and Certain Officers - EDAP 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A. and Certain Officers - EDAP 3Mast Therapeutics Announces Management Change 2Mast Therapeutics Announces Management Change 3Mast Therapeutics Announces Management Change 4
... announced the initiation of a landmark Phase 2 ... developed to improve neurological function in patients with ... In accordance with its internal focus on scientific ... at a peer-attended symposium at the American Spinal ...
... April 23, 2012 Medela convened the 7th ... on April 20-21, 2012. The annual event, attended ... lactation consultants, highlighted the latest insights into breastfeeding ... supporting breastfeeding women and their families through research ...
Cached Medicine Technology:Asubio Initiates Landmark Clinical Study in Spinal Cord Injury 2Asubio Initiates Landmark Clinical Study in Spinal Cord Injury 3Latest Findings in Breastfeeding Science Presented at Medela's 7th International Breastfeeding and Lactation Symposium 2Latest Findings in Breastfeeding Science Presented at Medela's 7th International Breastfeeding and Lactation Symposium 3
The Victory single- and dual-chamber rate-responsive pacemakers from St. Jude Medical are advanced-feature systems, designed to save valuable clinic time, maximize patient safety, and provide other t...
... To help cardiologists meet the ... Toshiba introduces the high performance Infinix ... solutions combine easy-to-use controls, one-touch operations, ... to optimize workflow and allow physicians ...
Cardiac 5-Axis Bi-plane: Infinix CF-i/BP...
... on the promise of Flat Panel ... outstanding image quality, at lower doses, ... small devices and structures. The new ... at lower dose than other systems ...
Medicine Products: